Mecamylamine (AGI-004)

Preliminary results for controlled release mecamylamine in Functional Diarrhoea were reported in February 2007.

The data from this study demonstrated a strong and statistically significant signal in improved stool consistency in patients with functional diarrhoea (per protocol) but without a matching response in the primary endpoint of patient global impression. AGI believes that controlled release mecamylamine has the potential to be an effective agent in diarrhoeal states character-ised by a high frequency of watery stools.

Given the mechanism of action of mecamylamine on nACh (nicotinic acetylcholine) receptors and the pathophysiology of certain diarrhoeal states which are not satisfied by current therapy, AGI has identified CID as an area of unmet clinical need where controlled release mecamylamine may have therapeutic benefit and is finalising plans for progression to Phase II clinical development in this indication.